Latest news with #EXAS
Yahoo
3 days ago
- Business
- Yahoo
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
Exact Sciences Corporation's EXAS efforts to further promote its flagship Cologuard as the standard of care are encouraging. The company plans to transform cancer care by providing patients with valuable insights at every step of their diagnosis and treatment. Additionally, it continues to invest in a pipeline of innovative solutions for every stage of cancer diagnosis. However, unfavorable solvency and mounting costs from macroeconomic pressures raise concerns for EXAS' operations. In the past year, this Zacks Rank #3 (Hold) stock has rallied 23.5% against the 17.1% fall of the industry and the S&P 500 Composite's gain of 11.3%. The globally renowned medical device company boasts a market capitalization of $10.34 billion. It has a long-term earnings growth rate of 29.3% compared with the industry's 21.4%. Additionally, the company's earnings surpassed estimates in three of the trailing four quarters and fell short in another, delivering an average surprise of 48.8%. Strategic Priority Bodes Well: Exact Sciences is pushing Cologuard as the CRC screening benchmark, backed by 16 million test uses over the past decade. In the first quarter of 2025, screening revenues increased 14%, led by broad-based Cologuard growth. Continued success in rescreens, care gap programs and growth in new ordering providers fuels this momentum. Exact Sciences is investing in the leadership team, training and sales force efficiency, as well as simplifying the electronic ordering process to further drive growth. Rescreening patients every three years from age 45 is also expected to contribute. Image Source: Zacks Investment Research Meanwhile, the robust international adoption of Oncotype DX led to 4% year-over-year growth in Precision Oncology revenues. The test, included in all major breast cancer treatment guidelines, helps early-stage breast cancer patients by evaluating the need for chemotherapy and recurrence risk. With about 70% of the eligible patients outside the United States not currently being tested, there still remains a substantial opportunity to grow. Enhancing Customer Experience: The company is currently working to build the best digital infrastructure and diagnostics. This vision has two main elements: first, enabling patients to take a more proactive role in their care. Second, it makes it easy for physicians to order tests, interpret results and personalize medicine by applying real-world evidence and guideline recommendations. The combined strength of Exact Nexus, the company's proprietary technology platform, and EXAS' commercial capabilities is leading to more patients completing Cologuard every three years, supporting the company's goal of making screening a routine practice and also closing the screening gap. The company has identified more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through large, organized screening programs. Advancing New Solutions: In late March 2025, the company launched Cologuard Plus, the most accurate non-invasive CRC screening test reported in studies so far. The test rapidly secured Medicare coverage, pricing and quality measure guideline inclusion. With its enhanced specificity, Cologuard Plus is expected to reduce unnecessary follow-up colonoscopies by up to 40% compared to the original Cologuard test. Subsequent to the quarter's end, Exact Sciences marked another highly anticipated launch with its Oncodetect MRD test. Introduced as a laboratory-developed test (LDT), the company expects to obtain Medicare reimbursement through the Molecular Diagnostic Services Program in the second quarter of 2025. Furthermore, the Cancerguard MCED test is on track to be launched as an LDT later this year. The company is also making headway with its blood-based colon cancer screening test, with top-line results from the pivotal BLUE-C study expected by mid-2025. Strong Solvency but Highly Leveraged: Exact Sciences exited the first quarter of 2025 with cash and cash equivalents and marketable securities of $786 million and zero current debt. However, the company's significant indebtedness is a concern. Long-term debt of $2.32 billion was almost consistent with the fourth-quarter levels. Escalating Costs: Exact Sciences' business has been affected by global macroeconomic conditions. Disruptions in the United States, Europe or other economies, whether from geopolitical tensions or changing international trade policies, could disrupt global markets, interrupt global supply chains and lead to inflationary or recessionary effects on the worldwide economy. In addition, the high-interest rate environment and limited access to capital markets could strain the company's suppliers, distributors and key business partners, making it difficult for them to remain in business. All these are creating significant pressure on its profitability as well. In the past 30 days, the Zacks Consensus Estimate for Exact Sciences' loss for 2025 went from 61 cents to 14 cents in the past 60 days. The Zacks Consensus Estimate for the company's 2025 revenues suggests a 12.4% year-over-year improvement to $3.10 billion. Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. Phibro Animal Health has an estimated long-term earnings growth rate of 26% compared with the industry's 15.7%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 30.6%. Its shares have rallied 37.7% compared with the industry's 10.7% growth in the past year. PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. Hims & Hers Health, currently carrying a Zacks Rank #2, has an earnings yield of 1.3% against the industry's 11.9% yield. Shares of the company have surged 151.7% compared with the industry's 32.5% gain. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched on one occasion and missed on another, the average surprise being 2.8%. Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry's 4.1%. Shares of the company have rallied 25.8% against the industry's 22.4% fall. COR's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
4 days ago
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments. Confident Investing Starts Here: Exact Sciences (EXAS) In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84. According to Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics. Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94. In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03. According to Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
Business Wire
28-05-2025
- Business
- Business Wire
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) test, Oncodetect™, in predicting recurrence in stage II–IV colorectal cancer. These data confirm the test's role in supporting treatment and surveillance decisions. Building on this momentum and its commitment to innovation, Exact Sciences will introduce a next-generation version of the test leveraging the Broad Institute's MAESTRO technology. Early data show the test will track up 5,000 2 patient specific variants and detect ctDNA * levels below 1 part per million. 1 The test will be available to both new and existing customers in 2026. 'We launched the Oncodetect test to give clinicians and patients a powerful tool for detecting cancer recurrence earlier and with greater precision—progress that's already being realized,' said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences. 'We continue to innovate and look forward to introducing the next iteration of the Oncodetect test, which leverages whole-genome sequencing and proprietary technology developed in collaboration with the Broad Institute to enhance sensitivity and expand clinical utility.' The Beta-CORRECT study demonstrates that the Oncodetect test significantly improves prognosis prediction compared to traditional standard of care methods †,3,4,5 Data presented at ASCO from the Beta-CORRECT clinical validation study confirm that the Oncodetect test accurately predicts recurrence in stage III colorectal cancer 3 —consistent with findings from the Alpha-CORRECT study —and extends this association to stages II and IV. 4 Exact Sciences' largest MRD clinical study to date, with more than 400 patients, demonstrates those with ctDNA-positive results after therapy and during surveillance showed a 24- and 37-fold increased risk of recurrence, respectively. 4 By quantifying ctDNA levels across multiple timepoints, the Oncodetect test enables physicians to more effectively guide treatment decisions and surveillance strategies in clinical practice. 3,4 Advancing the Oncodetect test with next generation innovation The next-generation MRD test, currently in validation across multiple solid tumor types, will track up to 5,000 patient-specific variants 2 with a limit of detection below 1 part per million, 1 enabling scalable monitoring and broad clinical utility. Exact Sciences holds exclusive rights to the Broad Institute's MAESTRO technology, a whole-genome sequencing method able to detect low-frequency ctDNA mutations with high accuracy. This technology advances the ability to look broadly across thousands of mutations while reducing the sequencing depth required to achieve an ultra-low limit of detection at a highly attractive cost point. Through continued innovation in MRD, Exact Sciences is advancing solutions with the potential to change clinical practice. 'The precision and sensitivity seen in the next generation test reflect deep scientific collaboration and a shared commitment to advancing MRD technology,' said Viktor Adalsteinsson, Ph.D., Director, Gerstner Center for Cancer Diagnostics at the Broad Institute. 'This approach to innovation will continue to raise the bar for recurrence monitoring, treatment response assessment, and, ultimately, patient outcomes.' * Circulating tumor DNA † Standard of care markers include CEA and clinicopathologic factors References: Edward S. Sim, Justin Rhoades, Kan Xiong, Laurel Walsh, Andjela Crnjac, Timothy Blewett, Yana Al-Inaya, Julia Mendel, Daniel A. Ruiz-Torres, Vasileios Efthymiou, Gjystina Lumaj, William J. Benjamin, G. Mike Makrigiorgos, Shervin Tabrizi, Viktor A. Adalsteinsson, Daniel L. Faden; Early Postoperative Minimal Residual Disease Detection with MAESTRO Is Associated with Recurrence and Worse Survival in Patients with Head and Neck Cancer. Clin Cancer Res 2025; Data source on file. Exact Sciences. Madison, WI. May 2025. Diergaarde B, Young G, Hall DW, et al. Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: the α-CORRECT study. J Surg Oncol. Jan 2025. Hashimoto et. al: The Association of ctDNA with Recurrence in Patients with Stage II-IV Colorectal Cancer: The ꞵ-CORRECT study. Presented at ASCO 2025. ASCO 2025 Industry Expert Theater Presentation: Molecular Residual Disease Testing with Exact Sciences' Oncodetect test: Product and Clinical Data Overview. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences helps give patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard ® and Oncotype DX ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook. Oncodetect and Oncotype DX are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences and Cologuard are trademarks of Exact Sciences Corporation. Oncodetect is only available in the United States. Forward-Looking Statement This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding our expectations for the commercialization of the Oncodetect and next-generation MRD tests, the performance characteristics and health care benefits of the Oncodetect and next-generation MRD tests in a commercial setting, and launch date for the next-generation MRD test. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Yahoo
16-05-2025
- Business
- Yahoo
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company's full-year revenue guidance of $3.1 billion at the midpoint came in 1.3% above analysts' estimates. Its non-GAAP loss of $0.21 per share was significantly below analysts' consensus estimates. Is now the time to buy EXAS? Find out in our full research report (it's free). Revenue: $706.8 million vs analyst estimates of $688.5 million (10.9% year-on-year growth, 2.7% beat) Adjusted EPS: -$0.21 vs analyst estimates of -$0.10 (significant miss) Adjusted EBITDA: $63.26 million vs analyst estimates of $59.87 million (8.9% margin, 5.7% beat) The company lifted its revenue guidance for the full year to $3.1 billion at the midpoint from $3.06 billion, a 1.3% increase EBITDA guidance for the full year is $440 million at the midpoint, above analyst estimates of $422.9 million Operating Margin: -13.6%, up from -16.7% in the same quarter last year Free Cash Flow was -$365,000 compared to -$120 million in the same quarter last year Constant Currency Revenue rose 11% year on year (5.8% in the same quarter last year) Market Capitalization: $10.6 billion Exact Sciences began 2025 with notable momentum, attributing Q1 results to improved commercial execution and the launch of new products. Management emphasized that changes made to the sales organization, including territory realignment and expanded field engagement, led to a 30% increase in customer interactions. CEO Kevin Conroy cited early success with the launch of Cologuard Plus and continued growth in the company's rescreen and care gap programs as key drivers of revenue for the quarter. Looking ahead, management lifted full-year revenue guidance and highlighted the expected impact of new products and operational efficiency initiatives. CFO Aaron Bloomer said the company expects 'continued leverage across the P&L,' with gross margin improvements and cost optimization actions underway. Management believes the recent launches and increased provider engagement will support both top-line growth and improving profitability throughout the year. Management identified several drivers of Q1 performance, including new product launches, enhanced commercial strategy, and operational improvements. Early signs of adoption for Cologuard Plus and increased engagement with healthcare providers contributed meaningfully to results. Commercial execution enhancements: The expansion and realignment of the sales force, along with targeted provider outreach, led to a 30% increase in provider engagement and higher sales productivity. Management stated that rep productivity was up about 10% and that three out of four new ordering providers were engaged within two weeks. Cologuard Plus launch: The company launched Cologuard Plus, its next-generation colorectal cancer screening test, which achieved early Medicare coverage and quality measure inclusion. Over 30,000 tests have already been completed, with ongoing discussions to secure broader payer coverage. Management emphasized the improved accuracy and lower false positive rate compared to the original Cologuard. Growth in recurring revenue streams: The rescreen program now accounts for more than 25% of total revenue, providing a stable and growing source of recurring income. Management noted increasing adherence rates and a growing eligible patient pool. Operational efficiency gains: Cost optimization and productivity initiatives reduced general and administrative expenses as a percentage of revenue by more than 520 basis points. The company also achieved break-even free cash flow, a $120 million year-over-year improvement. Pipeline and product development progress: Beyond Cologuard Plus, the company launched Oncodetect (a molecular residual disease test), continued work on a blood-based colon cancer screening test (with results expected mid-year), and prepared for the late-2025 launch of Cancerguard for multi-cancer screening. Management's outlook for the remainder of 2025 centers on sustained commercial momentum, expanded adoption of new products, and further cost discipline. The company expects these factors to drive high-single-digit to low-double-digit revenue growth and continued margin improvement. Broader adoption of Cologuard Plus: Management anticipates that securing coverage from additional payers and increasing provider awareness will lead to higher test volumes and improved gross margins due to better pricing and lower test costs. Expansion of recurring programs: Growth in the rescreen and care gap programs is expected to provide predictable revenue and higher customer retention, supporting stability even as new products scale. Operational efficiency initiatives: Further cost optimization, particularly in G&A and manufacturing, is expected to enhance profitability. Management also highlighted the risk of near-term cash flow fluctuations as accounts receivable build with new product launches, but expects collection to normalize by year-end. Tycho Peterson (Jefferies): Asked for details on commercial changes driving new customer growth. Management explained that doctor engagement and rep productivity increased, with new providers being contacted within two weeks of first orders. Catherine Schulte (Baird): Inquired about the breakdown of revenue guidance upgrades. CFO Aaron Bloomer attributed improvements to commercial execution, particularly in rescreens and care gap programs, and increased provider engagement. Brandon Couillard (Wells Fargo): Sought clarity on increased sales and marketing spend. Management responded that investments supported new product launches and were leveraged by strong revenue growth, with a goal of maintaining consistent pacing throughout the year. Patrick Donnelly (Citi): Requested updates on the pipeline and timing for the blood-based colon cancer screening test. CEO Kevin Conroy confirmed the company remains on track for a mid-summer top-line data readout. Luke Sergott (Barclays): Asked about gross margin trends with new product launches. Management stated that Cologuard Plus should be accretive to gross margin, as lower test costs and improved pricing offset potential headwinds from simultaneous product lines. In the coming quarters, the StockStory team will be monitoring (1) the pace of payer adoption and provider uptake for Cologuard Plus, (2) the volume growth and adherence rates in recurring rescreen and care gap programs, and (3) the upcoming mid-year release of top-line data from the company's blood-based colon cancer screening trial. Progress in operational efficiency and continued improvement in free cash flow generation will also be important signposts for tracking execution. Exact Sciences currently trades at a forward P/E ratio of 85.4×. Should you load up, cash out, or stay put? The answer lies in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
TansMedics Group is helping improve patient outcomes in the organ transplant field. Exact Sciences has helped increase colorectal cancer detection. 10 stocks we like better than TransMedics Group › While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more. That description fits TransMedics Group (NASDAQ: TMDX) and Exact Sciences (NASDAQ: EXAS), two innovative healthcare leaders. Here's why these companies could deliver strong returns through the end of the decade. TransMedics Group developed a revolutionary way to store organs before transplants. The company's Organ Care System (OCS) mimics the physiology of the human body, resulting in a higher usage rate for the organs it is approved for -- lungs, hearts, and kidneys -- than the traditional cold storage method. In a clinical trial, 32% of hearts kept in cold storage were used in a transplant, versus 81% for the OCS. The company's technology is superior; that's why it has gained traction. TransMedics Group has encountered some issues recently. The company's revenue growth slowed, while its guidance disappointed investors. Further, the medical device specialist became the target of serious allegations from an activist short-seller. However, TransMedics Group is rebounding, partly thanks to recent stronger-than-expected first-quarter results. TransMedics Group's stock jumped by about 20% on the heels of its most recent quarterly update. Still, the company's shares remain down by 11% in the past year, and there could be significant upside potential for the company in the next five years. TransMedics Group estimates that deceased donations of organs will continue to increase in the next few years. Meanwhile, there are more people in need of organs than the number of those willing to donate theirs. For the ones available, keeping them in the best possible shape for transplants is incredibly important. TransMedics Group's OCS is one of the better options on the market for doing just that. So, the company should continue growing its revenue and earnings at a good clip in the next five years, and likely beyond that. And in the meantime, the company could deliver excellent returns to investors. Investors can buy one of TransMedics Group's shares at current levels with $200. Exact Sciences is a healthcare company that develops cancer diagnostic tests. The company is best known for Cologuard, a non-invasive, at-home test for colorectal cancer (CRC) -- the second leading cause of cancer death worldwide. The fact that the disease is highly treatable when caught early, and yet kills as many patients as it does, suggests that not enough eligible people are getting screened. For those at average risk of CRC, it is recommended to start screening at 45 years old. Exact Sciences has made significant headway in this market. It first earned clearance for Cologuard in the U.S. in 2014; by 2022, it had been used to screen 10 million patients. Exact Sciences has encountered some headwinds in the past few years, including slower revenue growth and persistent net losses. However, recent developments could help the company fix this issue. In October, it earned approval for the next-gen version of its crown jewel, Cologuard Plus. This newer test proved superior at identifying true positives and false negatives, and should, therefore, help attract even more prescriptions from otherwise skeptical physicians. The new Cologuard is also 5% cheaper to manufacture. That should make a meaningful difference in the company's costs across millions of tests. Further, Exact Sciences recently launched Oncodetect, which is designed to check for cancer recurrence in patients across several solid tumors. Lastly, Exact Sciences plans to debut another product later this year, a multicancer-detecting test called Cancerguard. With these new products and the company's well-established Cologuard franchise, expect stronger revenue growth and, eventually, net profits before the end of the decade. The stock could deliver superior returns. Exact Sciences' shares are trading hands for just under $54, so $200 is good for three. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $598,613!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $753,878!* Now, it's worth noting Stock Advisor's total average return is 922% — a market-crushing outperformance compared to 169% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 12, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy. 2 Brilliant Stocks to Buy With $200 and Hold for 5 Years was originally published by The Motley Fool
